Jefferies Group’s Carisma Therapeutics CARM Stock Holding History

Jefferies Group’s Portfolio CARM Stock Details CARM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2021 Q2	–	Sell	-1,090	Closed	-$56.7K	–	1694
2021 Q1	$56.7K	Buy	+1,090	New	+$51.4K	﹤0.01%	1497

Other funds holding CARM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

TRV GP Boston, Massachusetts $18.9M AUM 541.67% 1-Year Est. Return

SSA

Schonfeld Strategic Advisors New York $14.2B AUM 37.17% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Jefferies Group's CARM Position: Q2 2021 in Review

Jefferies Group sold out of Carisma Therapeutics (CARM) in Q2 2021, closing a stake of 1,090 shares — an estimated $56.7K sold.

Jefferies Group first reported a position in CARM in Q1 2021 and held it in 1 quarter. The position peaked at $56.7K in Q1 2021. 105 funds tracked by Wall St. Rank hold CARM as of Q2 2021.

Jefferies Group reported no remaining Carisma Therapeutics position as of Q2 2021 after selling out during the quarter.
Jefferies Group sold 1,090 Carisma Therapeutics shares in Q2 2021, an estimated $56.7K.
Jefferies Group first reported a position in Carisma Therapeutics in Q1 2021 and held it in 1 quarter.
Jefferies Group's Carisma Therapeutics position peaked at $56.7K in Q1 2021.
105 funds tracked by Wall St. Rank held Carisma Therapeutics as of Q2 2021.

Based on Jefferies Group's 13F filing for Q2 2021, filed 16 Aug 2021.